NASDAQ:UMRX Cogent Biosciences Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.49 +0.10 (+1.19 %) (As of 02/24/2021 12:00 AM ET) Add Compare Share Today's Range$8.39Now: $8.49▼$8.8350-Day Range$2.35MA: $10.50▼$13.0152-Week Range$0.29Now: $8.49▼$3.72Volume458,809 shsAverage Volume1.22 million shsMarket Capitalization$360.56 millionP/E RatioN/ADividend YieldN/ABeta3.93 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.Read More HeadlinesUnum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational ProgressOctober 5, 2020 | prnewswire.comUnum Therapeutics now named as Cogent BiosciencesOctober 5, 2020 | seekingalpha.comUnum Therapeutics Inc. (UMRX)October 1, 2020 | finance.yahoo.comBlueprint Medicines Reports Positive Test Results For Rare Disease Treatment; BPMC Stock JumpsSeptember 22, 2020 | finance.yahoo.comUnum Therapeutics' BOXR CAR-T platform and products rights acquired by SOTIOAugust 31, 2020 | seekingalpha.comSOTIO Acquires Rights to BOXR CAR-T Platform and Products from Unum TherapeuticsAugust 31, 2020 | finance.yahoo.comUnum Therapeutics Transfers BOXR Cell-Based Therapy Technology to SOTIOAugust 31, 2020 | finance.yahoo.comIs Unum Therapeutics (UMRX) Stock Outpacing Its Medical Peers This Year?August 25, 2020 | finance.yahoo.comThinking about buying stock in Hudson Ltd, Unum Therapeutics, GrowGeneration, TOP Ships, or Norwegian Cruise Line?August 19, 2020 | marketwatch.comVenrock Healthcare Capital Partners acquires 0.451M shares of Unum TherapeuticsAugust 19, 2020 | seekingalpha.comThe Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOsAugust 19, 2020 | feeds.benzinga.comUnum Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate UpdatesAugust 11, 2020 | finance.yahoo.comSee More Headlines Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:UMRX Previous Symbol CUSIPN/A CIK1622229 Webwww.unumrx.com Phone(617) 945-5576Employees72Year FoundedN/ADebt Debt-to-Equity Ratio0.18 Current Ratio2.90 Quick Ratio2.90 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$22.50 million Price / Sales16.02 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book8.16Profitability EPS (Most Recent Fiscal Year)($1.04) Net Income$-31,830,000.00 Net Margins-96.84% Return on Equity-87.78% Return on Assets-52.14% Miscellaneous Outstanding Shares42,469,000Market Cap$360.56 million Next Earnings DateN/A OptionableNot Optionable MarketRank™Overall MarketRank™0.92 out of 5 starsMedical Sector1058th out of 1,958 stocksPharmaceutical Preparations Industry489th out of 772 stocksAnalyst Opinion: 1.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 - 1.4 Analyst's Opinion Consensus RatingCogent Biosciences has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Cogent Biosciences has a forecasted downside of 52.9% from its current price of $8.49.Amount of Analyst CoverageCogent Biosciences has received no research coverage in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesCogent Biosciences has received 186 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCogent Biosciences has received 173 “underperform” votes. (Add your “underperform” vote.)Community SentimentCogent Biosciences has received 51.81% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cogent Biosciences and other stocks. Vote “Outperform” if you believe UMRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe UMRX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCogent Biosciences does not currently pay a dividend.Dividend GrowthCogent Biosciences does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cogent Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 31.50% of the stock of Cogent Biosciences is held by insiders.Percentage Held by InstitutionsOnly 26.39% of the stock of Cogent Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cogent Biosciences are expected to grow in the coming year, from ($0.26) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cogent Biosciences is -11.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cogent Biosciences is -11.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCogent Biosciences has a P/B Ratio of 8.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Receive UMRX News and Ratings via Email Sign-up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter. Cogent Biosciences (NASDAQ:UMRX) Frequently Asked Questions Is Cogent Biosciences a buy right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cogent Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cogent Biosciences stock. View analyst ratings for Cogent Biosciences or view top-rated stocks. What stocks does MarketBeat like better than Cogent Biosciences? Wall Street analysts have given Cogent Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cogent Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. How were Cogent Biosciences' earnings last quarter? Cogent Biosciences, Inc. (NASDAQ:UMRX) posted its quarterly earnings data on Tuesday, August, 11th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.03. The company earned $0.53 million during the quarter. Cogent Biosciences had a negative trailing twelve-month return on equity of 87.78% and a negative net margin of 96.84%. View Cogent Biosciences' earnings history. What price target have analysts set for UMRX? 4 brokers have issued 1 year price targets for Cogent Biosciences' stock. Their forecasts range from $4.00 to $4.00. On average, they expect Cogent Biosciences' share price to reach $4.00 in the next year. This suggests that the stock has a possible downside of 52.9%. View analysts' price targets for Cogent Biosciences or view top-rated stocks among Wall Street analysts. Who are Cogent Biosciences' key executives? Cogent Biosciences' management team includes the following people: Andrew R. Robbins, President, Chief Executive Officer & DirectorGeoffrey Hodge, Chief Technical Officer & Senior VP-OperationsJohn L. Green, Chief Financial & Accounting OfficerJessica Sachs, Chief Medical OfficerGreg Motz, Head-Research Who are some of Cogent Biosciences' key competitors? Some companies that are related to Cogent Biosciences include Pliant Therapeutics (PLRX), MannKind (MNKD), BioXcel Therapeutics (BTAI), Omeros (OMER), Zealand Pharma A/S (ZEAL), Cassava Sciences (SAVA), Ocular Therapeutix (OCUL), Arcturus Therapeutics (ARCT), Phathom Pharmaceuticals (PHAT), Keros Therapeutics (KROS), Indivior (INVVY), Rhythm Pharmaceuticals (RYTM), Mersana Therapeutics (MRSN), Zogenix (ZGNX) and Constellation Pharmaceuticals (CNST). View all of UMRX's competitors. What other stocks do shareholders of Cogent Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cogent Biosciences investors own include Matinas BioPharma (MTNB), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), Cannabics Pharmaceuticals (CNBX), KushCo (KSHB), Novan (NOVN), Aeterna Zentaris (AEZS) and Zosano Pharma (ZSAN). When did Cogent Biosciences IPO? (UMRX) raised $75 million in an IPO on Thursday, March 29th 2018. The company issued 5,800,000 shares at $12.00-$14.00 per share. Morgan Stanley and Cowen acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers. What is Cogent Biosciences' stock symbol? Cogent Biosciences trades on the NASDAQ under the ticker symbol "UMRX." What is Cogent Biosciences' stock price today? One share of UMRX stock can currently be purchased for approximately $8.49. How much money does Cogent Biosciences make? Cogent Biosciences has a market capitalization of $360.56 million and generates $22.50 million in revenue each year. The company earns $-31,830,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis. How many employees does Cogent Biosciences have? Cogent Biosciences employs 72 workers across the globe. What is Cogent Biosciences' official website? The official website for Cogent Biosciences is www.unumrx.com. Where are Cogent Biosciences' headquarters? Cogent Biosciences is headquartered at 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA, 02140. How can I contact Cogent Biosciences? Cogent Biosciences' mailing address is 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA, 02140. The company can be reached via phone at (617) 945-5576 or via email at [email protected] This page was last updated on 2/25/2021 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here
